Andrew J Wagner

27PUBLICATIONS

179CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPharmacogenomicsPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (27)

Sort by Publication Date:

|Jul 06, 2026

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

|Jun 10, 2026

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Apr 24, 2026

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

|Jul 04, 2025

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

Andrew J Wagner, William D Tap, Sebastian Bauer

|Dec 11, 2024

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.

J Andrew Livingston, Jean-Yves Blay, Jonathan Trent

|Nov 12, 2024

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.

Jayesh Desai, Andrew J Wagner, Irene Carrasco Garcia

Pageof 5

Frequent Collaborators

Jean-Yves Blay

Silvia Stacchiotti

Brian A Van Tine

Javier Martín-Broto

Robin L Jones

William D Tap

Thierry Alcindor

Gregory M Cote

John H Healey

Hans Gelderblom

Frequent Collaborators

Jean-Yves Blay

Silvia Stacchiotti

Brian A Van Tine

Javier Martín-Broto